Previous 10 | Next 10 |
Shares of Atossa Genetics (NASDAQ: ATOS ) surged significantly on Thursday (March 14) after the US Food and Drug Administration (FDA) granted an approved-expanded access program for the company’s oral version of Endoxifen. According to the press release, the agency gave Atossa Genet...
Gainers: Atossa Genetics (NASDAQ: ATOS ) +242% . Hancock Jaffe Laboratories (NASDAQ: HJLI ) +41% . WageWorks (NYSE: WAGE ) +30%. Smith Micro Software (NASDAQ: SMSI ) +31% . Akari Therapeutics (NASDAQ: AKTX ) +30% . KalVista Pharmaceuticals (NASDAQ: KALV ) +29% . MongoDB (NASDA...
Atossa Genetics (NASDAQ: ATOS ) +223% on expanded access for Endoxifen. More news on: Atossa Genetics Inc., Hancock Jaffe Laboratories, Inc., Safe-T Group Ltd, Stocks on the move, Read more ...
Nano cap Atossa Genetics (NASDAQ: ATOS ) is up 227% premarket on increased volume in response to the FDA's sign-off on expanded access to Endoxifen for the post-mastectomy treatment of a single premenopausal estrogen receptor-positive (ER+) breast cancer patient. More news on...
SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has issued a “Safe to Procee...
SAN FRANSISCO, CA / ACCESSWIRE / February 27, 2019 / Vista Partners ("Vista") has published February 2019's FREE Macroeconomic & Investment Monthly Newsletter, "On Fed's Wings." Vista's monthly newsletter contains macroeconomic views & investment considerations that center around ...
MagneGas Applied Technology Solutions (NASDAQ: MNGA ) -46% . More news on: MagneGas Corporation, Cellect Biotechnology Ltd., Biocept, Inc., Stocks on the move, Read more ...
Nano cap Atossa Genetics ( ATOS +23.5% ) is up on a 7x surge in volume following its update on an estrogen receptor-positive (ER+) breast cancer patient who received preoperative oral Endoxifen under an FDA expanded access program. More news on: Atossa Genetics, Inc., Healthcare stocks...
Atossa Genetics (NASDAQ: ATOS ) +29% on updating the status of the pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient who received preoperative oral Endoxifen therapy under an FDA-approved “expanded access” program. More news on: Atossa Genetics, ...
SEATTLE, Feb. 07, 2019 (GLOBE NEWSWIRE) -- , February 7, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today updated the status o...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...